About
AI and data platform for ophthalmic imaging analysis. The segment's biggest 2025 exit: acquired by EssilorLuxottica in Oct 2025.
HQ: Bern, Switzerland
Funding
Acquired by EssilorLuxottica (Oct 2025); terms undisclosed
—Company profile
RetinAI Discovery — an FDA-cleared and CE-marked AI/data platform for AMD, DR and glaucoma; acquired by EssilorLuxottica (Oct 2025).
AI and data platform for ophthalmic imaging analysis. The segment's biggest 2025 exit: acquired by EssilorLuxottica in Oct 2025.
HQ: Bern, Switzerland